Asa Ren and G42 Healthcare Team Up to Advance Genomic Sequencing and Bioinformatics in Indonesia
JAKARTA, Indonesia, Nov. 17, 2022 /PRNewswire/ -- Asa Ren Pte Ltd ("Asa Ren"), a leading consumer DNA data company based in Indonesia, has announced a strategic partnership with leading UAE-based Artificial Intelligence technology company, G42 Health Care AI Holding RSC LTD ("G42 Healthcare"). This collaboration is intended to develop and enhance the genomic sequencing and bioinformatics capability in Indonesia in...
MED-EL Presents: ideas4ears and calls for child inventors to aim high for people living with hearing loss
Global children's contest launched on World Inventors Day to raise awareness of hearing loss and the benefits of treatment INNSBRUCK, Austria, Nov. 17, 2022 /PRNewswire/ -- MED-EL, a leading provider and inventor of hearing implant systems, today launched its annual worldwide search for inventions of the future through a global children's contest,...
In operation the most innovative 11.74T MRI Core Magnet to be used on humans
GENOA, Italy, Nov. 17, 2022 /PRNewswire/ -- The world's first simultaneous multi-channel/multi-nuclear 11.74T MRI system is currently under development at Gachon University Gil Medical Center (GUGMC). In the first Half of 2022 GUGMC successfully completed the Site Acceptance Test of the Magnet, which is a core part of the brain-specific ultra-precision 11.74T...
WiSE® Technology to Feature in Upcoming APHRS Scientific Session
SUNNYVALE, Calif., Nov. 17, 2022 /PRNewswire/ -- EBR Systems, Inc. (ASX: "EBR", "EBR Systems", or the "Company"), developer of the world's only wireless cardiac pacing system for heart failure, is pleased to announce that the Company's WiSE® technology will be featured at the 15th Asia Pacific Heart Rhythm Society (APHRS) Scientific Session in Singapore from the 18th to the...
Qmed Asia Eyes APAC Expansion with Digital Health Solutions
KUALA LUMPUR, Malaysia, Nov. 17, 2022 /PRNewswire/ - In the wake of a successful month, Qmed Asia announces regional expansion into Taiwan, Indonesia, Vietnam, and Cambodia to introduce value-added services to healthcare segments and patients in the form of innovative digital health solutions that are accessible, affordable, and reliable. ...
Asia Pacific experts uncover gender-based disparity in diagnosis, treatment, and management of Atrial Fibrillation
A new report, including insights from international experts, reveals that Atrial Fibrillation diagnosis is more challenging in women, needing a tailored management approach SINGAPORE, Nov. 17, 2022 /PRNewswire/ -- Biosense Webster, Inc., part of Johnson & Johnson MedTech, today announced the release of a report titled, 'Atrial Fibrillation Exacts Toll on Women: Addressing the Gender Disparity in the Treatment...
[CES 2023] AI FOR PET NAMED AS CES 2023 INNOVATION AWARDS HONOREE
SEOUL, South Korea, Nov. 17, 2022 /PRNewswire/ -- AI FOR PET today announced that it has been named as CES 2023 Innovation Awards Honoree for TTcare. This year's CES Innovation Awards program received a record-high number of over 2100 submissions. The announcement was made ahead of CES 2023, the world's most influential technology event, happening Jan. 5-8 in Las...
Standigm Synthetic Research Center successfully accelerates drug discovery in its first year
Lab uniquely enables collaboration between chemical and AI researchers SEOUL, South Korea, Nov. 17, 2022 /PRNewswire/ -- Standigm, the workflow AI-driven drug discovery company, today announced the celebration of its Synthetic Research Center's first year. In the last 12 months, the company has collaborated with outside researchers to create hundreds of novel molecules...
Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA
--While the ASC61 Phase I study is ongoing in the U.S., the Investigational New Drug (IND) approval in China will accelerate the global development of ASC61, an in-house developed oral PD-L1 small molecule inhibitor HANGZHOU and SHAOXING, China, Nov. 17, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the approval of the Investigational New Drug...
RemeGen’s Disitamab Vedotin Achieves First-Line Treatment Recommendation Status for Advanced Urothelial Cancer in Updated 2022 CSCO Guidelines
YANTAI, China, Nov. 17, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a Chinese commercial-stage biotechnology company, announced on November 5 that the Company's self-developed novel antibody-drug conjugate (ADC) Disitamab Vedotin (RC48) has been officially included in the newly released Chinese Society of Clinical Oncology (CSCO) 2022 Guidelines for the Treatment and Management of Urothelial...
